Nasal Spray as an Alternative Delivery Route for Dry Eye and Neuroprotection: A Narrative Review
Journal of Biological Methods · 10.07.2026 · e99010105
DOI: 10.14440/jbm.026040003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Methods, online erschienen am 10.07.2026. Verfasst von Matteo Capobianco und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Background/Objectives: Intranasal (IN) neuroactivation of trigeminal/nasolacrimal pathways—either pharmacologically (e.g., varenicline nasal spray) or via intranasal electrical neurostimulation—has been shown to increase tear production in dry eye disease (DED) and to improve patient-reported symptoms, with variable effects on ocular surface staining across studies. Intranasal administration can exploit olfactory and trigeminal pathways to access central nervous system (CNS); preclinical studies also report delivery to the optic nerve and ocular compartments (e.g., vitreous) with associated retinal ganglion cell/optic nerve neuroprotection, supporting further investigation of intranasal strategies for ocular neuroprotection.
Methods
We conducted a narrative review on the basis of databases of PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library, with ClinicalTrials.gov screened for complete and ongoing studies) through 5 January 2026. The search terms included “intranasal/nasal spray”, “dry eye/tear secretion”, “trigeminal/neurostimulation”, and “neuroprotection/retina/optic nerve”, prioritizing clinical trials, mechanistic studies, and comprehensive reviews.
Results
Phase IIb–III randomized, vehicle-controlled trials of varenicline solution nasal spray (OC-01) exhibited statistically significant improvements in tear production (Schirmer test) vs. vehicle and improvements in patient-reported symptoms (with statistical significance found in several symptom endpoints), with tolerability characterized mainly by mild, transient non-ocular adverse events. The product received Food and Drug Administration (FDA) approval for dry eye disease in 2021. Open-label and meta-analytic evidence also supports efficacy of intranasal tear neurostimulation in DED. Preclinical and translational studies demonstrated that IN administration could rapidly deliver proteins and other agents to the eye, optic nerve, and brain, with neuroprotective benefits achieved in optic-nerve and retinal injury models. Reported advantages include bypass of the first-pass metabolism and the blood–brain barrier with non-invasive dosing. Major limitations include mucociliary clearance, dose volume constraints, inter-individual variability, and local nasal adverse events.
Conclusions
Evidence supports IN delivery as a clinically relevant modality for DED and a promising platform for ocular neuroprotection. Priorities include standardized ocular/retinal pharmacokinetics after IN dosing, head-to-head comparisons with topical/injectable standards, long-term safety surveillance (including olfactory and nasal mucosa), and optimization of candidate molecules and regimens.
Zitieren
APA
Capobianco, M., Zeppieri, M., Maniaci, A., Luca, A., D’Esposito, F., Cappellani, F., Nicolosi, S. G., & Gagliano, C. (2026). Nasal Spray as an Alternative Delivery Route for Dry Eye and Neuroprotection: A Narrative Review. Journal of Biological Methods, 0(0), e99010105. https://doi.org/10.14440/jbm.026040003
Vancouver
Capobianco M, Zeppieri M, Maniaci A, Luca A, D’Esposito F, Cappellani F, et al. Nasal Spray as an Alternative Delivery Route for Dry Eye and Neuroprotection: A Narrative Review. Journal of Biological Methods. 2026;0(0):e99010105. doi:10.14440/jbm.026040003
BibTeX
@article{Capobianco2026,
author = {Capobianco, Matteo and Zeppieri, Marco and Maniaci, Antonino and Luca, Antonina and D’Esposito, Fabiana and Cappellani, Francesco and Nicolosi, Simonetta Gaia and Gagliano, Caterina},
title = {Nasal Spray as an Alternative Delivery Route for Dry Eye and Neuroprotection: A Narrative Review},
journal = {Journal of Biological Methods},
year = {2026},
volume = {0},
number = {0},
pages = {e99010105},
doi = {10.14440/jbm.026040003}
}
EUVIMED